An open label, long-term treatment evaluation of the safety of BEMA [BioErodible MucoAdhesive] fentanyl use for breakthrough pain in cancer subjections on chronic opioid therapy

Trial Profile

An open label, long-term treatment evaluation of the safety of BEMA [BioErodible MucoAdhesive] fentanyl use for breakthrough pain in cancer subjections on chronic opioid therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2012

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions
  • Sponsors BioDelivery Sciences International
  • Most Recent Events

    • 14 Jun 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.
    • 14 Jun 2008 The expected completion date for this trial is now 1 Jun 2008.
    • 17 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top